Bispecific Antibodies: Clinical Trial Tracker

  • ID: 2760412
  • Clinical Trials
  • Roots Analysis
1 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Eli Lilly
  • ImClone System
  • Merrimack Pharmaceuticals
  • PharmAbcine
  • MORE
Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.

Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system.

As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases.

The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjugates. A number of such trials which are taking place for a variety of indications across multiple geographies have been identified.

For each specific trial the following information is provided:

- Trial Objective
- Manufacturer / Licensee
- Technology
- Target Antigen
- Indication
- Sponsor / Collaborator
- Trial Phase
- Trial Status
- Start Date
- End Date
- Enrolment
- Age Group
- Inclusion Criteria
- Exclusion Criteria
- Study Design
- Primary Endpoint
- Secondary Endpoint
- Treatment Arms
- Route of Administration
- Location(s)
- Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

Detailed forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.
Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders

Research Methodology

Most of the data presented in this report has been gathered by secondary research. Interviews with experts in the area (academia, industry, medical practice and other associations) has also been conducted to solicit their opinions on emerging trends in the market. This is primarily useful to draw out opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides an independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

* Format:

- EXCEL Based Tracker
- PDF Presentation
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Eli Lilly
  • ImClone System
  • Merrimack Pharmaceuticals
  • PharmAbcine
  • MORE
I. Introduction and Pipeline Details

Section 1: Market Overview
Section 2: Dashboard: Pipeline Analysis
Section 3: Molecules in Clinical Development: Trial Details
Section 4: Molecules in Preclinical Development: Trial Details
Section 5: Inclusion / Exclusion Criteria

II Market Forecast, 2013 - 2023

Section 6: Market Forecast: Assumptions
Section 7: Market Forecast: Details
Section 8: Comparative Forecast Scenarios

III. Industry Analysis

Section 9: Industry SWOT Analysis

List of Figures

Figure 1: Bispecific Antibodies in Clinical Development: Distribution by Companies
Figure 2: Bispecific Antibodies in Clinical Development: Distribution by Highest Phase of Development
Figure 3: Bispecific Antibodies in Clinical Development: Distribution by Type of Bispecific System
Figure 4: Bispecific Antibodies in Clinical Development: Distribution by Indication
Figure 5: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase and Status (Matrix View)
Figure 6: Bispecific Antibodies Clinical Trials: Distribution by Trial Status
Figure 7: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase
Figure 8: Bispecific Antibodies Clinical Trials: Distribution by Indication
Figure 9: Bispecific Antibodies Clinical Trials: Distribution by Sponsor Type
Figure 10: Bispecific Antibodies Clinical Trials: Distribution by Region
Figure 11: Bispecific Antibodies Clinical Trials: Distribution by Molecules and Countries (Matrix View)
Figure 12: Bispecific Antibodies Clinical Trials: Distribution by G7 Countries
Figure 13: Bispecific Antibodies Clinical Trials: Distribution by EU5 Countries
Figure 14: Bispecific Antibodies in Preclinical Development: Distribution by Indication
Figure 15: Bispecific Antibody Therapeutics Market Forecast, Base Scenario (USD MM)
Figure 16: Bispecific Antibody Therapeutics Market Forecast, Scenario Comparison (USD MM)

List of Tables

Table 1: Molecules in Clinical Development: Pipeline Details
Table 2: Molecules in Preclinical Development: Pipeline Details
Table 3: Expected Launch Year of Bispecific Antibodies in Clinical Development
Table 4: SWOT Analysis
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AbbVie
- Ablynx
- Adimab
- Affimed Therapeutics
- AGO Study Group
- Allergan
- Alligator Bioscience
- Allozyne
- Ambrx
- Amgen
- Amphivena Therapeutics Inc.
- Baliopharm
- Barbara Ann Karmanos Cancer Institute
- Bayer
- Beijing ABT Genetic Engineering Technology Co.
- Biogen Idec
- Bioline Rx
- Biotecnol
- Boehringer Ingelheim
- Celgene
- Centre René Gauducheau
- Chiome Bioscience
- Chugai
- Dutalys
- Eddingpharm
- Eli Lilly
- Emergent Biosolutions
- Fabion Pharmaceuticals
- Fresenius Biotech
- F-star
- Ganymed Pharmaceuticals
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Genentech
- Genmab
- Gilead
- Grupo Español de Investigación en Cáncer de Ovario; Neovii Biotech
- GSK
- Gustave Roussy, Cancer Campus, Grand Paris
- Ho Research Consortium
- ImClone System
- Immunomedics
- Innovent Biologics Inc.
- Institut National de la Santé Et de la Recherche Médicale, France
- International Joint Cancer Institute, the Second Military Medical University
- Janssen Biotech
- Jsehouli
- Krankenhaus Nordwest
- Kyowa Hakko Kirin
- MacroGenics
- Masonic Cancer Center, University of Minnesota
- MediaPharma S.R.L
- MedImmune
- Memorial Sloan-Kettering Cancer Center
- Merck
- Merrimack Pharmaceuticals
- Merus B.V.
- Molecular Partners AG
- Nantes University Hospital
- National Cancer Institute
- National Engineering Research Center for Antibody Medicine
- NeoPharm
- Neovii Biotech
- Novartis
- NovImmune
- Numab
- OncoMed Pharmaceuticals
- Paktis Antibody Services GmbH
- Pfizer
- PharmAbcine
- PLA General Hospital Cancer Center, Beijing
- Protheragen
- Radboud University
- Regeneron Pharmaceuticals
- Roche
- Roger Williams Medical Center
- Sanofi
- School of Medicine, Shanghai Jiao Tong University
- Sea Lane Biotechnologies
- Servier
- State Key Laboratory of Antibody Medicine and Targeted Therapy
- Sutro Biopharm
- Synergys Biotherapeutics Inc.
- Synimmune GmbH
- Technische Universität München
- Trion Pharma
- University Hospital Tuebingen
- University Witten/Herdecke
- Xencor
- Zymeworks
- Zyngenia
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll